secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2024-05-28T23:59:59+00:00
Accession:  0001193125-24-148107
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine CEO Kevin Gorman to retire Oct 11; Kyle Gano appointed successor
---------------------------------------------------------------------------

- Kevin C. Gorman, Ph.D. to retire as President and CEO effective October 11, 2024; will remain on the board.
- Kyle Gano, Ph.D., current Chief Business Development and Strategy Officer, becomes President and CEO on same date.
- Gano appointed to the board as a Class II director effective October 11, 2024.
- Board size increased from 10 to 11 via bylaw amendment to accommodate Gano's appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/0001193125-24-148107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/d836271d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-148107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer